New hope for fungal lung disease: biologics study aims to tame severe asthma complication
NCT ID NCT07362693
Summary
This study will observe how well biologic drugs work for people with allergic bronchopulmonary aspergillosis (ABPA), a serious fungal complication of severe asthma. It will follow 50 adults to see if these drugs reduce the number of disease flare-ups, lower the need for steroid medications, and improve asthma control. The main goal is to gather real-world evidence on the effectiveness and safety of these treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS (ABPA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China
Jinan, Shandong, 250014, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.